News AbbVie bullish on Humira and near-term pipeline Sales of Humira could peak above $18 billion - CEO
News Amjevita, first Humira biosimilar approved – but no launch y... Amgen's biosimilar is ready to go, but AbbVie believes it can delay until 2022
News AbbVie waits on data from Humira successor Ablynx's vobarilizumab seen as key should Humira sales fall.
News Biogen eyeing big-selling biosimilars as MS drug fails Gamble on opicinumab looks unlikely to pay off.
News Amgen biosimilar stands up against Humira Amgen's biosimilar candidate ABP 501 has shown comparable results in phase III, measured against AbbVie's blockbuster Humira (adalimumab), for patients with moderate-to-severe plaque psoria
News OpenBind unveils its first AI model for drug discovery A research consortium that aims to make the UK a leader in AI-driven drug discovery, OpenBind, has hit its first major milestone.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
